The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures

Sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (Other)
Overall Status
Recruiting
CT.gov ID
NCT05082337
Collaborator
Institut de Cardiologie de Montréal (Other)
20
Enrollment
2
Locations
1
Arm
4.7
Anticipated Duration (Months)
10
Patients Per Site
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

TAVR patients exhibiting post-procedural residual AR had higher mortality and hospitalization rates due to heart failure, with the extent of this association increasing proportionally to the severity of the regurgitation. Optimizing transcatheter valve performance by intra-procedural hemodynamic evaluation of AR and residual transvalvular gradient remains of high clinical importance.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: SAVVY guidewire
N/A

Detailed Description

Continuous technological development and procedural refinements are important to further reduce TAVR peri-procedural complications, facilitate the minimalist strategy and improve clinical outcomes following TAVR. Residual aortic regurgitation (AR) has been one of the main drawbacks of TAVR. TAVR patients exhibiting post-procedural residual AR had higher mortality and hospitalization rates due to heart failure, with the extent of this association increasing proportionally to the severity of the regurgitation.

Various actions could be undertaken to minimize AR and its consequences, either intraprocedural (balloon post-dilation, implantation of a second valve) or during follow-up (diuretic treatment, closest clinical follow-up or percutaneous leakage closure). Thus, an accurate diagnosis of the presence and severity of residual AR post-TAVR is key to implement the proper measures and optimize clinical outcomes.

The use of cardiac imaging remains the gold standard for evaluating AR post-TAVR, limitations of contrast amount along with the subjectivity of AR evaluation by aortic angiography, and the challenges of echocardiography at the time of the TAVR procedure represent a significant drawback. Thus, alternative tools for evaluating the presence and severity of AR would be very helpful in this setting.

Current data supports the implementation of hemodynamic measurements during TAVR procedures in order to improve the clinical decision-making process following valve implantation. However, these actions entail an inherent risk associated with the exchange of catheter-wires. The use of a support guidewire with pressure measurement capabilities would facilitate the hemodynamic evaluation of transcatheter valve performance in a safer and more rapid manner.

The new SAVVY guidewire, with both dedicated pacing properties and allowing a continuous hemodynamic pressure monitoring during the procedure, is a unique system in the field and may represent an important step forward in the process of optimizing the TAVR procedure while facilitating procedural steps.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Patient with severe symptomatic aortic stenosis with a clinical indication for TAVR according to the Heart Team criteria will be treated with an approved aortic valve (balloon-expandable or self-expandable aortic valve) and the SAVVY guidewire will be used for the rapid pacing runs and ventricular pressure measurements.Patient with severe symptomatic aortic stenosis with a clinical indication for TAVR according to the Heart Team criteria will be treated with an approved aortic valve (balloon-expandable or self-expandable aortic valve) and the SAVVY guidewire will be used for the rapid pacing runs and ventricular pressure measurements.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures: A Feasibility Study
Actual Study Start Date :
Oct 8, 2021
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Feb 28, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Guidewire

The SAVVY guidewire will be used in all TAVR procedures of patients included in the study

Device: SAVVY guidewire
The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment

Outcome Measures

Primary Outcome Measures

  1. Presence of Major complications [Periprocedural]

    Presence of major complications related to the SAVVY guidewire including (i) guidewire kink hindering or preventing the advancement of the transcatheter valve system

  2. Presence of Major vascular complications [Periprocedural]

    Major vascular complications related to the SAVVY guidewire are defined as stroke, bleeding or left ventricular perforation

  3. Number of transcatheter valve malpositioning [Periprocedural]

    Pacing capture failure translating into valve malpositioning. Valve malpositiong will be evaluated by a landing site to low or too high, leading to hemodynamically unfavorable results.

  4. Number of valve embolization [Periprocedural]

    Pacing capture failure translating into valve embolization

  5. Number of effective rapid pacing run [Periprocedural]

    Effective rapid pacing will be defined as an adequate ventricular pacing capture for a minimum of 10 seconds, with no capture loss, and leading to a reduction of aortic pressure of at least 50%, with/or a systolic pressure value <60 mmHg. Efficacy will be assessed by the physician.

  6. Number of accurate ventricular pressure [Periprocedural]

    Accurate ventricular pressure will be defines as a pressure wire measurements similar (differences <5 mmHg) to those obtained simultaneously with a pigtail catheter in the same cavity or vascular segment (differences <5 mmHg in SBP, differences <5 mmHg in LVEDP).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with severe symptomatic AS undergoing a TAVR procedure.
Exclusion Criteria:
  • Failure to provide signed informed consent.

  • Extremely calcified aortic valve (Agatston score >3000 AU)

  • Extremely horizontal aorta.

  • Severe septal hypertrophy (interventricular septum >15 mm as measured by TTE).

  • Extreme tortuosity at the level of the iliofemoral arteries, thoracic or abdominal aorta.

  • Prohibitive surgical risk precluding (according to the Heart Team) conversion to open heart surgery in case of a life threatening complication.

  • Young patients (<18 Years) and pregnant women

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1ICMMontréalQuebecCanadaH1T 1C8
2IUCPQQuebecCanadaG1V 4G5

Sponsors and Collaborators

  • Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
  • Institut de Cardiologie de Montréal

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Josep Rodes-Cabau, Principal investigator, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
ClinicalTrials.gov Identifier:
NCT05082337
Other Study ID Numbers:
  • PRT-2015-02
First Posted:
Oct 18, 2021
Last Update Posted:
Oct 18, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2021